Correction to: Nature https://doi.org/10.1038/s41586-025-09203-8 Published online 2 July 2025
In the version of this article initially published, a patient’s KRAS mutation was mistakenly documented as a PIK3CA mutation in the original data. In Table 1, the incorrect entries in the “PIK3CA mutation present, n (%)” section—P value (0.459); Mutated: Yes (6 (54.5)), No (5 (45.5)); Wild-type: Yes (16 (69.6)), No (7 (30.4))—have been updated to P value (0.717); Mutated: Yes (5 (45.5)), No (6 (54.5)); Wild-type: Yes (13 (56.5)), No (10 (43.5)). In the “Survival after ICB in the OCCC cohort” section of main text, in the sentence now reading “Next-generation sequencing analysis of tumour biopsies identified ARID1A and PIK3CA somatic mutations or alterations in the majority of patients (73.5% and 52.9%, respectively)” 52.9% replaces “55.9%”. Additionally, there were a few mutations with mislabeled mutation types in Extended Data Fig. 1b. Extended Data Fig. 1b and accompanying source data have been updated. These errors do not affect the results or conclusions of the study. The changes have been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Dai, Y., Knisely, A., Yano, M. et al. Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 645, E10 (2025). https://doi.org/10.1038/s41586-025-09586-8
Published:
Issue date:
DOI: https://doi.org/10.1038/s41586-025-09586-8
